Cathepsin D in Breast Cancer Tissue

1990 ◽  
Vol 5 (4) ◽  
pp. 203-206 ◽  
Author(s):  
P. Gonzalez Gancedo ◽  
M.L. G-Casaus ◽  
J. Ruiz Cacho ◽  
F. Calero ◽  
J.M. Inocente ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cathepsin D ◽  
Clinical Stage ◽  
Point Of View ◽  
Axillary Lymph Nodes ◽  
Cancer Tissue ◽  
Axillary Lymph ◽  
Statistical Point ◽  
High Concentrations ◽  
Dependent State

The cathepsin D concentration in 18 women with benign breast pathology has a cut-off value of 43 pmol/mg of protein. High values have been detected in two cases of chronic mastitis. These high values of cathepsin D were found in a study of 62 patients suffering from breast cancer and are independent of the hormone dependent state of the tumour. The cathepsin D concentration may have a prognostic function in breast cancer determination, as high concentrations are found in combination with other prognostic factors such as clinical stage, size of the tumour, state of the axillary lymph nodes and in the histological differentiation grade, where from a statistical point of view, the combination is important.

Measuring standards of care for early breast cancer in an insured population.

1997 ◽  
Vol 15 (4) ◽  
pp. 1401-1408 ◽  
Author(s):  
B E Hillner ◽  
M K McDonald ◽  
L Penberthy ◽  
C E Desch ◽  
T J Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ct Scan ◽  
Bone Scan ◽  
Best Practice ◽  
Clinical Stage ◽  
Primary Treatment ◽  
Standards Of Care ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
International Consensus

PURPOSE To demonstrate the use of a combined data base to evaluate the care for local/regional invasive breast cancer in a large insured population of women aged less than 64 years. PATIENTS AND METHODS We linked the procedural and hospital claims from Blue Cross Blue Shield (BCBS) of Virginia with clinical stage data from the Virginia Cancer Registry (VCR) from 1989 to 1991. A total of 918 women were assessed with a median age of 50 years; 68% had tumors less than 2 cm, 30% had positive axillary nodes, and 68% were assessed as having local summary stage. A quality-of-care "report card" was used based on standards of care from international Consensus Conferences. RESULTS Eight percent had a mastectomy as the initial biopsy procedure. Sixty-nine percent of women ultimately underwent mastectomy. Of those women who underwent lumpectomy, 86% had subsequent radiation. Within 3 months of diagnosis, 43% had a bone scan and 20% a computed tomography (CT) scan. Of women with positive axillary lymph nodes, 83% aged less than 51 years and 52% aged 51 to 64 years received chemotherapy. Fifty-six percent of all women had claims from a medical oncologist. Of women having a total mastectomy, 27% had claims from a plastic surgeon. Sixty-six percent to 76% of women had a mammogram, 24% a bone scan, and 14% a CT scan in the 0-18 and 18-36 month intervals following primary treatment. CONCLUSION This study confirms the feasibility of linking sources of data that provide complementary information needed to develop measurements regarding standards of quality and efficiency of oncologic care. This report should serve as an initial benchmark while we await reports from other populations to define the best practice.

scholarly journals Axillary Imaging Following a New Invasive Breast Cancer Diagnosis—A Radiologist’s Dilemma

2021 ◽  
Author(s):  
Vandana Dialani ◽  
Basak Dogan ◽  
Katerina Dodelzon ◽  
Brian N Dontchos ◽  
Neha Modi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Invasive Breast Cancer ◽  
Molecular Subtype ◽  
Treatment Plan ◽  
Clinical Stage ◽  
Breast Cancer Diagnosis ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Axillary Metastasis ◽  
Image Guided

Abstract Traditionally, patients with newly diagnosed invasive breast cancer underwent axillary US to assess for suspicious axillary lymph nodes (LNs), which were then targeted for image-guided needle biopsy to determine the presence of metastasis. Over the past decade, there has been a shift towards axillary preservation. For patients with palpable lymphadenopathy, the decision to perform axillary imaging with documentation of the number and location of abnormal LNs in preparation for image-guided LN sampling is straightforward. Since LN involvement correlates with cancer size, it is reasonable to image the axilla in patients with tumors larger than 5 cm; however, for tumors smaller than 5 cm, axillary imaging is often deferred until after the tumor molecular subtype and treatment plan are established. Over the last decade, neoadjuvant chemotherapy (NACT) is increasingly used for smaller cancers with more aggressive molecular subtypes. In most cases, detecting axillary metastasis is critical when deciding whether the patient would benefit from NACT. There is increasing evidence that abnormal axillary US findings correlates with LN metastases and reliably establishes a baseline to monitor response to NACT. Depending on hormone receptor status, practices may choose to image the axilla in the setting of clinical stage T1 and T2 cancers to evaluate nodal status and help determine further steps in care. Radiologists should understand the nuances of axillary management and the scope and challenges of LN marking techniques that significantly increase the precision of limited axillary surgery.

scholarly journals Sentinel Lymph Node Biopsy using Indocyanine Green and Blue Dye in Male Breast Cancer: A Case Report of 5 Patients

2021 ◽  
Author(s):  
Jun Yang ◽  
Xu-Li Meng ◽  
Yong Yu ◽  
Lei Pan ◽  
Jun Wu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Sentinel Lymph Node ◽  
Indocyanine Green ◽  
Male Breast Cancer ◽  
Clinical Stage ◽  
Male Breast ◽  
Axillary Lymph Nodes ◽  
Blue Dye ◽  
Axillary Lymph

Abstract Background: Male breast cancer is extremely rare and optimal treatments remain unclear. Most of research findings about breast cancer are derived from female patients and has not been rigorously investigated in male patients. The aim of article is to introduce the utility of indocyanine green (ICG) and blue dye mapping for sentinel lymph node (SLN) biopsy and to determine its clinical usefulness in male breast cancer. Case presentation: A total of 5 consecutive male breast cancer patients with clinical stage ranging from I to IIA in the Tongde Hospital of Zhejiang Province during March 2013 to May 2016 were included in the present study. All patients underwent SLN biopsy with ICG and blue dye. Planed surgical resection with axillary lymph node dissection was performed. Surgically excised sentinel nodes were subjected to conventional histopathology. All of 5 cases with male breast cancer were successfully identified SLNs. Among them, 4 cases were detected by blue dye and all cases were detected by indocyanine green. A total of 10 SLNs were retrieved with an average nodal count of 2 per patient. Metastases were present in 2 nodes within 1 patients. Conclusions: These results provide evidence that the SLN biopsy mapping with ICG and blue dye is accurate in predicting axillary lymph nodes metastases and has the potential to be a reliable criteria for staging of the axilla in patients with male breast cancer.

Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors

2006 ◽  
Vol 24 (7) ◽  
pp. 1037-1044 ◽  
Author(s):  
Valentina Guarneri ◽  
Kristine Broglio ◽  
Shu-Wan Kau ◽  
Massimo Cristofanilli ◽  
Aman U. Buzdar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Stage ◽  
Pathologic Complete Response ◽  
Prognostic Significance ◽  
Complete Response ◽  
Primary Chemotherapy ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Risk Of Death ◽  
Group 5

Purpose To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR). Patients and Methods This retrospective analysis included 1,731 patients with stage I to III noninflammatory breast cancer treated between 1988 and 2005 with primary chemotherapy (PC). Ninety-one percent of patients received anthracycline-based PC, and 66% received additional taxane therapy. pCR was defined as no evidence of invasive tumor in the breast and axillary lymph nodes. Results Median age was 49 years (range, 19 to 83 years). Sixty-seven percent of patients (n = 1,163) had HR-positive tumors. A pCR was observed in 225 (13%) of 1,731 patients; pCR rates were 24% in HR-negative tumors and 8% in HR-positive tumors (P < .001). A significant survival benefit for patients who achieved pCR compared with no pCR was observed regardless of HR status. In the HR-positive group, 5-year overall survival (OS) rates were 96.4% v 84.5% (P = .04) and 5-year progression-free survival (PFS) rates were 91.1% v 65.3% (P < .0001) for patients with and without pCR, respectively. For the HR-negative group, 5-year OS rates were 83.9% v 67.4% (P = .003) and 5-year PFS rates were 83.4% v 50.0% (P < .0001) for patients with and without pCR, respectively. After adjustment for adjuvant hormonal treatment, HR status, clinical stage, and nuclear grade, patients who achieved a pCR had 0.36 times the risk of death. Conclusion pCR is associated with better outcome regardless of HR status in breast cancer patients who receive PC.

Sign in / Sign up

Export Citation Format

Share Document